Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathwayss

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 3, 2013, Pages 404-418

  Cupp, Meghan E ^a   Nayak, Surendra K ^a   Adem, Amina S ^a   Thomsen, William J ^a  

^a SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE RELATED PEPTIDE[1-34]; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; ANIMALS; ARRESTIN; BONE DENSITY CONSERVATION AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DRUG DESIGN; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; INOSITOL PHOSPHATES; MAP KINASE SIGNALING SYSTEM; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RECEPTOR, PARATHYROID HORMONE, TYPE 2; SIGNAL TRANSDUCTION;

EID: 84878059956     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.199752     Document Type: Article

References (50)

1. Abou-Samra AB, Jüppner H, Force T, Freeman MW, Kong XF, Schipani E, Urena P, Richards J, Bonventre JV, and Potts JT, Jr, et al. (1992) Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: A single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 89:2732-2736.
2. Bassoni DL, Raab WJ, Achacoso PL, Loh CY, and Wehrman TS (2012) Measurements of b-arrestin recruitment to activated seven transmembrane receptors using enzyme complementation. Methods Mol Biol 897:181-203.
3. Bisello A, Chorev M, Rosenblatt M, Monticelli L, Mierke DF, and Ferrari SL (2002) Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J Biol Chem 277:38524-38530.
4. Caporale A, Biondi B, Schievano E, Wittelsberger A, Mammi S, and Peggion E (2009) Structure-function relationship studies of PTH(1-11) analogues containing Damino acids. Eur J Pharmacol 611:1-7.
5. Caporale A, Sturlese M, Schievano E, Mammi S, and Peggion E (2010) Synthesis and structural studies of new analogues of PTH(1-11) containing Ca-tetra-substituted amino acids in position 8. Amino Acids 39:1369-1379.
6. Castro M, Nikolaev VO, Palm D, Lohse MJ, and Vilardaga JP (2005) Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc Natl Acad Sci USA 102:16084-16089.
7. Dempster DW, Cosman F, Parisien M, Shen V, and Lindsay R (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690-709.
8. Ferrari SL, Pierroz DD, Glatt V, Goddard DS, Bianchi EN, Lin FT, Manen D, and Bouxsein ML (2005) Bone response to intermittent parathyroid hormone is altered in mice null for beta-Arrestin2. Endocrinology 146:1854-1862.
9. Fitzpatrick LA and Bilezikian JP (1996) Principles of Bone Biology (Bilezikian JP, Raisz LG, and Rodan GA, eds, ed) pp 339-346, Academic Press, Inc., San Diego, CA.
10. Gardella TJ and Jüppner H (2001) Molecular properties of the PTH/PTHrP receptor. Trends Endocrinol Metab 12:210-217.
11. Gensure RC, Gardella TJ, and Jüppner H (2005) Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 328:666-678.
12. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, Eckhardt AE, Cowan CL, Spurney RF, and Luttrell LM, et al. (2006) Distinct beta-arrestin-and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281:10856-10864.
13. Gesty-Palmer D, Flannery P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ, and Lutrell LM (2009) A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1:1-20.
14. Guo J, Liu M, Yang D, Bouxsein ML, Thomas CC, Schipani E, Bringhurst FR, and Kronenberg HM (2010) Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH. Endocrinology 15. Endocrinology 151:3502-3513.
15. Hilliker S, Wergedal JE, Gruber HE, Bettica P, and Baylink DJ (1996) Truncation of the amino terminus of PTH alters its anabolic activity on bone in vivo. Bone 19: 469-477.
16. Hock JM and Gera I (1992) Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65-72.
17. Jilka RL (2007) Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434-1446.
18. Kawai M, Mödder UI, Khosla S, and Rosen CJ (2011) Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov 10:141-156.
19. Kenakin T (2007) Functional selectivity through protean and biased agonism: Who steers the ship? Mol Pharmacol 72:1393-1401.
20. Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:296-302.
21. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, and Onyia JE (2001) Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054.
22. McGuinness D, Malikzay A, Visconti R, Lin K, Bayne M, Monsma F, and Lunn CA (2009) Characterizing cannabinoid CB2 receptor ligands using DiscoveRx Path-Hunter beta-arrestin assay. J Biomol Screen 14:49-58.
23. Murrills RJ, Matteo JJ, Samuel RL, Andrews JL, Bhat BM, Coleburn VE, Kharode YP, and Bex FJ (2004) In vitro and in vivo activities of C-terminally truncated PTH peptides reveal a disconnect between cAMP signaling and functional activity. Bone 35:1263-1272.
24. Neerup TS, Stahlhut M, Petersen JS, Daugaard JR, Jensen JE, Peng Z, Morko J, and Thorkildsen C (2011) ZP2307, a novel, cyclic PTH(1-17) analog that augments bone mass in ovariectomized rats. Bone 48:1319-1327.
25. Nickolls SA, Waterfield A, Williams RE, and Kinloch RA (2011) Understanding the effect of different assay formats on agonist parameters: A study using the m-opioid receptor. J Biomol Screen 16:706-716.
26. Ogata N, Shinoda Y, Wettschureck N, Offermanns S, Takeda S, Nakamura K, Segre GV, Chung UI, and Kawaguchi H (2011) G alpha(q) signal in osteoblasts is inhibitory to the osteoanabolic action of parathyroid hormone. J Biol Chem 286: 13733-13740.
27. Okazaki M, Ferrandon S, Vilardaga JP, Bouxsein ML, Potts JT, Jr, and Gardella TJ (2008) Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci USA 105:16525-16530.
28. Olson KR and Eglen RM (2007) Beta galactosidase complementation: A cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol 5:137-144.
29. Pierroz DD, Rufo A, Bianchi EN, Glatt V, Capulli M, Rucci N, Cavat F, Rizzoli R, Teti A, and BouxseinML, et al. (2009) Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J Bone Miner Res 24:775-784.
30. Pioszak AA and Xu HE (2008) Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc Natl Acad Sci USA 105:5034-5039.
31. Pioszak AA, Parker NR, Gardella TJ, and Xu HE (2009) Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides. J Biol Chem 284:28382-28391.
32. Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, Dewire SM, Violin JD, and Lefkowitz RJ (2011) Quantifying ligand bias at seventransmembrane receptors. Mol Pharmacol 80:367-377.
33. Reiter E, Ahn S, Shukla AK, and Lefkowitz RJ (2012) Molecular mechanism of b-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52:179-197.
34. Rhee Y, Lee W, Lee EJ, Ma S, Park SY, and Lim SK (2006) In vitro and in vivo effect of parathyroid hormone analogue (1-14) containing-amino-iso-butyric acid residue (Aib)1,3. Yonsei Med J 47:214-222.
35. Rixon RH, Whitfield JF, Gagnon L, Isaacs RJ, Maclean S, Chakravarthy B, Durkin JP, Neugebauer W, Ross V, and Sung W, et al. (1994) Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase. J Bone Miner Res 9:1179-1189.
36. Shimizu N, Guo J, and Gardella TJ (2001) Parathyroid hormone (PTH)-(1-14) and-(1-11) analogs conformationally constrained by alpha-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor. J Biol Chem 276:49003-49012.
37. Shimizu N, Dean T, Khatri A, and Gardella TJ (2004) Amino-terminal parathyroid hormone fragment analogs containing alpha,alpha-di-alkyl amino acids at positions 1 and 3. J Bone Miner Res 19:2078-2086.
38. Sneddon WB, Magyar CE, Willick GE, Syme CA, Galbiati F, Bisello A, and Friedman PA (2004) Ligand-selective dissociation of activation and internalization of the parathyroid hormone (PTH) receptor: Conditional efficacy of PTH peptide fragments. Endocrinology 145:2815-2823.
39. Syme CA, Friedman PA, and Bisello A (2005) Parathyroid hormone receptor trafficking contributes to the activation of extracellular signal-regulated kinases but is not required for regulation of cAMP signaling. J Biol Chem 280:11281-11288.
40. Takasu H, Guo J, and Bringhurst FR (1999) Dual signaling and ligand selectivity of the human PTH/PTHrP receptor. J Bone Miner Res 14:11-20.
41. Tam CS, Heersche JN, Murray TM, and Parsons JA (1982) Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration. Endocrinology 110: 506-512.
42. Taylor CW and Tovey SC (2012) From parathyroid hormone to cytosolic Ca21 signals. Biochem Soc Trans 40:147-152.
43. Trinquet E, Bouhelal R, and Dietz M (2011) Monitoring Gq-coupled receptor response through inositol phosphate quantification with the IP-One assay. Expert Opin Drug Discov 6:981-994.
44. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, and Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
45. van der Lee MM, Verkaar F, Wat JW, van Offenbeek J, Timmerman M, Voorneveld L, van Lith LH, and Zaman GJ (2013) b-Arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor. Cell Signal 25:527-538.
46. Vilardaga JP, Romero G, Friedman PA, and Gardella TJ (2011) Molecular basis of parathyroid hormone receptor signaling and trafficking: A family B GPCR paradigm. Cell Mol Life Sci 68:1-13.
47. Wang J and Stern PH (2010) Osteoclastogenic activity and RANKL expression are inhibited in osteoblastic cells expressing constitutively active Ga(12) or constitutively active RhoA. J Cell Biochem 111:1531-1536.
48. Whitfield JF, Morley P, Willick GE, Ross V, Barbier JR, Isaacs RJ, and Ohannessian-Barry L (1996) Stimulation of the growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment, hPTH-(1-31)NH2 (Ostabolin). Calcif Tissue Int 58:81-87.
49. Yang D, Singh R, Divieti P, Guo J, Bouxsein ML, and Bringhurst FR (2007) Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone. Bone 40: 1453-1461.
50. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, Nguyen DG, Caldwell JS, and Chen YA (2009) Lipid G protein-coupled receptor ligand identification using betaarrestin PathHunter assay. J Biol Chem 284:12328-12338.